2016;133:2222 34. S4.3.2-28. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta- blockers. JAMA. 2004;292:1341 4. S4.3.2-29. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866 74. S4.3.2-30. Wedekind H, Burde D, Zumhagen S, et al. QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr. 2009;168:1107 15. S4.3.2-31. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syn- drome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51 9. S4.3.2-32. Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inher- ited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183 9. 5. THERAPIES FOR TREATMENT OR PREVENTION OF VA 5.1. Medication Therapy S5.1.5.2-1. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129 47. S5.1.5.2-2. Schleifer JW, Sorajja D, Shen WK. Advances in the pharmacologic treatment of ventricular arrhythmias. Expert Opin Pharmacother. 2015;16:2637 51. S5.1.5.2-3. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016; 1711 22. S5.1.5.2-4. Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016;67:1053 8. S5.1.5.2-5. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents cat- echolaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380 3. S5.1.5.2-6. Gupta T, Khera S, Kolte D, et al. Antiarrhythmic properties of ranolazine: a review of the current evidence. Int J Cardiol. 2015;187:66 74. S5.1.5.2-7. Bunch TJ, Mahapatra S, Murdock D, et al. 